WebNews

Please enter a web search for web results.

NewsWeb

The Spectator Australia
spectator. com. au > 2026 > 05 > gene-editing-drugs-are-opening-a-new-frontier-in-medicine

Gene-editing drugs are opening a new frontier in medicine

14+ hour, 54+ min ago  (332+ words) Older readers with bulging medicine cabinets, or parents eyeing their children's distant futures, are not encouraged to read the New England Journal of Medicine " despite its prestige. A paper just published there, however, matters to them and to me. "In…...

Symbols: nasdaq:crsp,nasdaq:vrtx
Science Daily
sciencedaily. com > releases > 2024 > 10 > 241025122645. htm

A lung pathogen's dilemma: Infect or resist antibiotics?

9+ hour, 2+ min ago  (412+ words) To survive tough conditions, P. aeruginosa forms colonies known as "biofilms" -- clusters of bacteria encased in a self-produced matrix that provides them with significant advantages, including protection from antibiotics. Mimicking natural infection environments to observe the bacteria To better understand P. aeruginosa's…...

Symbols: btc-usd
Med City News
medcitynews. com > 2026 > 04 > intellia-crispr-in-vivo-gene-editing-hereditary-angioedema-hae-rare-disease-ntla

Intellia's Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med

1+ mon, 1+ hour ago  (247+ words) Intellia Therapeutics" lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to the swelling attacks from the rare disease hereditary angioedema. Intellia has filed a regulatory submission for this genetic medicine, which…...

Symbols: lonvo-z
CNBC
cnbc. com > 04/27/2026 > crispr-gene-editing-intellia-trial. html

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

1+ mon, 3+ hour ago  (449+ words) Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U. S. Food and…...

Symbols: attr-cm,lonvo-z,nasdaq:ntla
@mathrubhumi
english. mathrubhumi. com > lifestyle > health > one-time-gene-therapy-ldl-cholesterol-lowering-sh8q28ss

One-dose gene therapy shows up to 62% cut in bad cholesterol in early trial

8+ hour, 45+ min ago  (493+ words) A Phase 1b clinical trial of Eli Lilly's gene therapy VERVE-102 has shown up to 62% reduction in LDL cholesterol with a single dose, raising hopes for long-term treatment of hypercholesterolaemia and heart disease risk. A one-time gene therapy for treating hypercholesterolaemia…...

Symbols: nasdaq:edit
abc10. com
abc10. com > article > news > nation-world > gene-editing-cholesterol-away-cleveland-alzheimers-findings-supplement-warning > 507-3d4f23a2-d98f-4b2e-8d0c-e0b74a92346b

Gene-editing cholesterol away, new Alzheimer's findings and a supplement warning

1+ day, 4+ hour ago  (383+ words) A single infusion. A dramatic drop in bad cholesterol. And results that may last a lifetime. An experimental gene-editing treatment is turning heads in the medical world " and researchers say it could one day change the way heart'disease is prevented…...

Symbols: snac-k,cdr-sb
@CDCgov
cdc. gov > international-infection-control > php > stories > southeast-asia-ar-workshop. html

Southeast Asian Hospital Teams Strengthen Efforts to Combat Antimicrobial Resistance

6+ hour, 33+ min ago  (251+ words) Southeast Asia is among the global regions with the highest CRO burden. In 2021, between 8, 300 to 21, 800 deaths in the region were attributable to CROs. [[1]] To help address this challenge, CDC hosted a regional workshop in Bangkok, Thailand in December 2024 to improve…...

Oncodaily - Oncology News
oncodaily. com > voices > al-ola-a-abdallah-509011

Al-Ola A Abdallah Comments On the New Article on Dual-Target CAR-T Strikes Hard in EMD - Onco Daily

20+ hour, 5+ min ago  (269+ words) Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on'X: "Dual-Target CAR-T Strikes Hard in EMD: ORR 97%, PFS 6 months! Is Persistence the Missing…...

Symbols: nasdaq:omer
Bio Space
biospace. com > press-releases > breezebio-announces-scientific-advisory-board-to-support-next-stage-of-precision-genetic-medicine-pipeline-development

Breeze Bio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development

1+ day, 3+ hour ago  (523+ words) Bio Space Breeze Bio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--#Nano Galaxy--Breeze Bio, Inc. , formerly known as Gen Edit, today announced the formation of its…...

Symbols: nasdaq:dtil
News-Medical
news-medical. net-medical. net

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

19+ hour, 53+ min ago  (483+ words) A single infusion of VERVE-102 sharply lowered PCSK9 and LDL cholesterol in a small phase 1 trial, offering early evidence for a potentially durable genetic approach to cholesterol control, while long-term safety and clinical benefit remain to be proven. Study: In Vivo…...

Symbols: nasdaq:edit